002393.SHE Tianjin Lisheng Pharmaceutical Co Ltd
- Market cap
- CNY 3.94B
- P/E
- 32.0x
- P/B
- 0.86x
- ROE
- 2.3%
- Dividend yield
- 2.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002393.SHE undervalued?
Graham number002393.SHE trades 10.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianjin Lisheng Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Tianjin Lisheng Pharmaceutical Co Ltd yet.
Tianjin Lisheng Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive system applications. Its products also include Shoubishan capsules, Jiayindapamide…
Full company profileTianjin Lisheng Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianjin Lisheng Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 847M | 1.03B | 1.50B | 1.62B | 1.14B | 1.09B | 1.15B | 1.15B | 1.34B | 1.39B | 1.18B |
| Gross Profit | 478M | 642M | 1.06B | 1.15B | 684M | 618M | 636M | 665M | 712M | 1.39B | 611M |
| Operating Income | 131M | 131M | 215M | 220M | 31.0M | 137M | 118M | 420M | 222M | 470M | 121M |
| EBITDA | 185M | 191M | 272M | 279M | 94.9M | 197M | 184M | 488M | 296M | 533M | 130M |
| Net Income | 116M | 117M | 185M | 188M | 8.62M | 122M | 93.6M | 362M | 185M | 418M | 105M |
| EPS | 0.45 | 0.46 | 0.72 | 0.74 | 0.04 | 0.48 | 0.36 | 1.40 | 0.72 | 1.62 | 0.34 |
| Balance Sheet | |||||||||||
| Total Assets | 3.49B | 3.68B | 3.92B | 5.27B | 5.02B | 5.19B | 5.29B | 5.78B | 5.79B | 5.58B | 5.32B |
| Total Liabilities | 471M | 602M | 705M | 856M | 720M | 780M | 942M | 877M | 986M | 891M | 794M |
| Shareholders' Equity | 3.02B | 3.08B | 3.21B | 4.42B | 4.30B | 4.41B | 4.35B | 4.90B | 4.77B | 4.63B | 4.49B |
| Cash & Short-term Investments | 872M | 1.48B | 1.55B | 1.69B | 1.56B | 1.65B | 1.99B | 2.22B | 2.21B | 2.56B | 1.21B |
| Total Debt | 91.4M | 90.0M | 81.2M | 26.9M | 19.2M | 34.7M | 45.1M | 32.6M | 48.2M | 174M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 174M | 179M | 163M | 268M | 76.4M | 196M | 331M | 210M | 88.3M | 452M | - |
| Capital Expenditure | 137M | 50.1M | 104M | 90.5M | 101M | 88.2M | 40.9M | 61.7M | 53.8M | 37.5M | 27.8M |
| Free Cash Flow | 36.4M | 129M | 58.3M | 178M | -24.3M | 108M | 290M | 138M | 34.5M | 414M | -109M |
| Ratios | |||||||||||
| ROE | 3.8% | 3.8% | 5.8% | 4.3% | 0.2% | 2.8% | 2.2% | 7.4% | 3.9% | 9.0% | 2.3% |
| ROA | 3.3% | 3.2% | 4.7% | 3.6% | 0.2% | 2.4% | 1.8% | 6.3% | 3.2% | 7.5% | 2.0% |
| Net Profit Margin | 13.7% | 11.3% | 12.3% | 11.6% | 0.8% | 11.2% | 8.2% | 31.4% | 13.8% | 30.0% | 8.8% |
| Debt to Equity | 0.03x | 0.03x | 0.03x | 0.01x | 0.00x | 0.01x | 0.01x | 0.01x | 0.01x | 0.04x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tianjin Lisheng Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.28%
- Forward dividend
- 0.85 CNY
- Payout ratio
- 21.4%
- Ex-dividend date
- Apr 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 89.7M | 0.35 | 21.4% |
| 2024 | CNY 121M | 0.47 | 65.6% |
| 2023 | CNY 54.7M | 0.21 | 15.1% |
| 2022 | CNY 54.7M | 0.21 | 58.5% |
| 2021 | CNY 18.2M | 0.07 | 14.9% |
| 2020 | CNY 54.7M | 0.23 | 635.3% |
| 2019 | CNY 54.7M | 0.21 | 29.1% |
| 2018 | CNY 57.3M | 0.22 | 31.0% |
| 2017 | CNY 58.3M | 0.23 | 49.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Apr 28, 2026.
Who owns Tianjin Lisheng Pharmaceutical Co Ltd
- Insiders 54.89%
- Institutions 0.68%
- Public & others 44.43%
- Shares outstanding 308M
- Free float 148M
Tianjin Lisheng Pharmaceutical Co Ltd company profile
- Company name
- Tianjin Lisheng Pharmaceutical Co Ltd
- Ticker
- 002393.SHE
- ISIN
- CNE100000NJ9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 23, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,605
- Fiscal year end
- December
- Address
- No.16, Saida North 1st Road, Tianjin, China, 300385
- Phone
- 86 22 2764 1760
- Website
- lishengpharma.com
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive system applications. Its products also include Shoubishan capsules, Jiayindapamide tablets, Sanyu Zhengtong tablets, Xifuni cefdinir dispersible tablets, and Youhao Maren soft capsules. In addition, the company provides pharmaceutical manufacturing outsourcing services and technology research and development services. Further, it exports its products. The company was founded in 1951 and is headquartered in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd.
Tianjin Lisheng Pharmaceutical Co Ltd management
7- Mr. Fujun WangGM & Non-Independent Director · born 1967
- Mr. Jiaying WangFinancial Director · born 1981
- Ms. Feifei MaSecretary of the Board · born 1980
- Mr. Changfeng LongChief Engineer & Deputy GM · born 1974
- Mr. Jiankang LiangDeputy General Manager · born 1973
- Ms. Xiaoyan GuoDeputy General Manager · born 1973
- Gao JunAccounting Supervisor